Adaptive Biotechnologies (ADPT) Free Cash Flow (2018 - 2026)

Adaptive Biotechnologies has disclosed Free Cash Flow across 9 years of filings, most recently posting -$7.6 million for Q2 2026.

• In Q2 2026, Free Cash Flow rose 42.04% year-over-year to -$7.6 million; the TTM figure through Jun 2026 stood at -$24.0 million (up 70.98% YoY), while the FY2025 annual figure was -$48.9 million, up 50.5% from the prior year.
• Free Cash Flow came in at -$7.6 million for Q2 2026 at Adaptive Biotechnologies, up from -$10.3 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $1.4 million in Q4 2025 to a low of -$67.5 million in Q1 2022.
• Average Free Cash Flow over 5 years is -$29.6 million, with a median of -$27.8 million recorded in 2023.
• Year-over-year, Free Cash Flow dropped 3.39% in 2023 and surged 111.29% in 2025.
• Over 5 years, Free Cash Flow stood at -$32.6 million in 2022, then gained by 13.3% to -$28.2 million in 2023, then jumped by 55.47% to -$12.6 million in 2024, then surged by 111.29% to $1.4 million in 2025, then tumbled by 634.46% to -$7.6 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$7.6 million in Q2 2026, -$10.3 million in Q1 2026, and $1.4 million in Q4 2025.